CD274 and non-small cell lung carcinoma: This study (a LUNG-MAP treatment trial) evaluates the efficacy and safety of talazoparib, a PARP inhibitor in combination with avelumab, a PD-L1 monoclonal antibody, for stage IV or recurrent non-squamous NSCLC with LKB1 mutations